HRP20170021T1 - Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol - Google Patents
Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol Download PDFInfo
- Publication number
- HRP20170021T1 HRP20170021T1 HRP20170021TT HRP20170021T HRP20170021T1 HR P20170021 T1 HRP20170021 T1 HR P20170021T1 HR P20170021T T HRP20170021T T HR P20170021TT HR P20170021 T HRP20170021 T HR P20170021T HR P20170021 T1 HRP20170021 T1 HR P20170021T1
- Authority
- HR
- Croatia
- Prior art keywords
- cyclodextrin
- composition according
- ethyl
- octylphenyl
- diol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 15
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 title claims 5
- 238000009472 formulation Methods 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 14
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 5
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 4
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000001116 FEMA 4028 Substances 0.000 claims 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 3
- 229960004853 betadex Drugs 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- -1 2-hydroxypropyl Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 2
- 150000005846 sugar alcohols Chemical class 0.000 claims 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Claims (14)
1. Čvrsti farmaceutski sastav prikladan za oralnu primjenu, naznačen time, da obuhvaća sljedeće:
a) prvi spoj odabran od 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diola, njegove farmaceutski prihvatljive soli, i njegovog fosfatnog derivata;
b) punilo; i
c) stabilizator koji sadrži ciklodekstrin ili njegov derivat;
pri čemu fosfatni derivat ima sljedeću formulu:
[image]
gdje je ciklodekstrin ili njegov derivat prirodni ciklodekstrin, razgranati ciklodekstrin, alkil-ciklodekstrin ili hidroksialkil-ciklodekstrin, i pri čemu sastav sadrži manje od 0,5 mg prvog spoja.
[image]
2. Sastav prema zahtjevu 1, naznačen time, da punilo sadrži šećerni alkohol.
3. Sastav prema zahtjevu 2, naznačen time, da punilo sadrži manitol kao šećerni alkohol.
4. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da nadalje sadrži vezivo.
5. Sastav prema zahtjevu 4, naznačen time, da vezivo obuhvaća hidroksipropilcelulozu.
6. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da nadalje sadrži lubrikant.
7. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da ciklodekstrin ili njegov derivat je sljedeći: α-ciklodekstrin, β-ciklodekstrin,
γ-ciklodekstrin, hidroksipropil-ciklodekstrin, sulfobutileter-β-ciklodekstrin,
dodekakis-2,6,O-metil-α-ciklodekstrin,
tetradekakis-2,6,O-metil-β-ciklodekstrin,
heksadekakis-2,6,O-metil-γ-ciklodekstrin,
tetradekakis-2,6,O-etil-β-ciklodekstrin, α-ciklodekstrin djelomično
eteriziran s 2-hidroksipropilom, β-cklodekstrin djelomično
eteriziran s 2-hidroksipropilom, razgranati α-ciklodekstrin ili razgranati
β-ciklodekstrin, gdje se glukoza ili maltoza spaja preko α-1,6-glukozid-veze.
8. Sastav prema bilo kojem od zahtjeva 1 do 6, naznačen time, da stabilizator obuhvaća hidroksipropil-β-ciklodekstrin.
9. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je stabilizator prisutan prema omjeru molarnog sadržaja, u količini od 0,4-puta do 3 puta od količine 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diola ili njegove farmaceutski prihvatljive soli.
10. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da prvi spoj je 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol ili njegova farmaceutski prihvatljiva sol.
11. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da se upotrebljava u liječenju autoimune bolesti.
12. Sastav prema zahtjevu 11, naznačen time, da autoimuna bolest je multipla skleroza.
13. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da je farmaceutski sastav u jediničnom doznom obliku, gdje svaka jedinica sadrži od 0,03 do 0,40 mg 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diola u slobodnom obliku, u obliku njegove farmaceutski prihvatljive soli i njegovog fosfatnog derivata koji ima sljedeću formulu:
[image]
14. Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da farmaceutski sastav je tableta ili kapsula.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470747P | 2011-04-01 | 2011-04-01 | |
| US201161545835P | 2011-10-11 | 2011-10-11 | |
| PCT/US2012/031340 WO2012135561A1 (en) | 2011-04-01 | 2012-03-30 | Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diol |
| EP12714163.8A EP2694037B1 (en) | 2011-04-01 | 2012-03-30 | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170021T1 true HRP20170021T1 (hr) | 2017-03-10 |
Family
ID=45953284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170021TT HRP20170021T1 (hr) | 2011-04-01 | 2017-01-09 | Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol |
| HRP20200249TT HRP20200249T1 (hr) | 2011-04-01 | 2020-02-14 | Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200249TT HRP20200249T1 (hr) | 2011-04-01 | 2020-02-14 | Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol |
Country Status (35)
| Country | Link |
|---|---|
| US (5) | US9592208B2 (hr) |
| EP (2) | EP3143990B1 (hr) |
| JP (1) | JP6019101B2 (hr) |
| KR (1) | KR102027014B1 (hr) |
| CN (1) | CN103476400B (hr) |
| AR (1) | AR085749A1 (hr) |
| AU (1) | AU2012236357B2 (hr) |
| BR (1) | BR112013024430B1 (hr) |
| CA (1) | CA2831600C (hr) |
| CL (1) | CL2013002810A1 (hr) |
| CO (1) | CO6771459A2 (hr) |
| CY (2) | CY1118423T1 (hr) |
| DK (2) | DK3143990T3 (hr) |
| EA (2) | EA027721B1 (hr) |
| EC (1) | ECSP13012912A (hr) |
| ES (2) | ES2773482T3 (hr) |
| GT (1) | GT201300227A (hr) |
| HK (1) | HK1190309A1 (hr) |
| HR (2) | HRP20170021T1 (hr) |
| HU (1) | HUE031286T2 (hr) |
| IL (1) | IL228250B (hr) |
| JO (1) | JO3177B1 (hr) |
| LT (2) | LT3143990T (hr) |
| MA (1) | MA34981B1 (hr) |
| MX (1) | MX342522B (hr) |
| MY (2) | MY175633A (hr) |
| PE (2) | PE20140162A1 (hr) |
| PL (2) | PL2694037T3 (hr) |
| PT (2) | PT2694037T (hr) |
| RS (1) | RS59917B1 (hr) |
| SG (1) | SG193256A1 (hr) |
| SI (2) | SI3143990T1 (hr) |
| TW (1) | TWI528958B (hr) |
| WO (1) | WO2012135561A1 (hr) |
| ZA (1) | ZA201306636B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014141298A2 (en) * | 2013-03-11 | 2014-09-18 | Astron Research Limited | Stable pharmaceutical composition of fingolimod |
| CN103222966A (zh) * | 2013-04-01 | 2013-07-31 | 北京万全德众医药生物技术有限公司 | 一种含有盐酸芬戈莫德的固体药物组合物及其制备方法 |
| WO2015015254A1 (en) | 2013-07-29 | 2015-02-05 | Aizant Drug Research Solutions Pvt Ltd | Pharmaceutical compositions of fingolimod |
| CN106794159A (zh) * | 2014-08-22 | 2017-05-31 | 广东东阳光药业有限公司 | 一种芬戈莫德固体组合物及其制备方法 |
| WO2016042493A1 (en) | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
| EP3247341A4 (en) * | 2015-01-20 | 2018-12-19 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| EP3419607B1 (en) | 2017-03-29 | 2019-11-20 | Deva Holding Anonim Sirketi | Stable formulations of fingolimod |
| US11135197B2 (en) | 2020-02-07 | 2021-10-05 | Argentum Pharmaceuticals Llc | Dosage regimen of an S1P receptor modulator |
| WO2021158848A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor agonist |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| EP0627406B1 (en) | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
| CZ285953B6 (cs) | 1995-12-28 | 1999-12-15 | Yoshitomi Pharmaceutical Industries, Ltd. | Vnější přípravek pro topické podání |
| US6476004B1 (en) * | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| GB9624038D0 (en) | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| EP2030614A1 (en) | 1997-02-27 | 2009-03-04 | Novartis AG | Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin |
| KR100551931B1 (ko) | 1997-04-04 | 2006-02-16 | 미츠비시 웰파마 가부시키가이샤 | 2-아미노프로판-1,3-디올 화합물, 이것의 의약으로서의 용도 및 합성 중간체 |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 松森 昭 | ウイルス性心筋炎の予防または治療薬剤 |
| AU2001285331B2 (en) | 2000-08-31 | 2006-04-06 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| DE122011100047I1 (de) * | 2003-04-08 | 2011-12-15 | Mitsubishi Tanabe Pharma Corp | Feste pharmazeutische darreichungsformen mit einemS1P rezeptoragonisten und einem zuckeralkohol. |
| JP4861177B2 (ja) * | 2003-09-12 | 2012-01-25 | ニューロノバ エービー | 神経系の障害の処置 |
| MX2007006706A (es) | 2004-12-06 | 2007-10-18 | Univ Virginia | Analogos de esfingosina 1-fosfato amida de arilo. |
| GB0502358D0 (en) * | 2005-02-04 | 2005-03-16 | Novartis Ag | Organic compounds |
| GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| EP3103448B1 (en) | 2006-09-26 | 2019-07-03 | Novartis Ag | Pharmaceutical compositions comprising an s1p modulator |
| EP2120575A4 (en) | 2006-12-21 | 2011-04-27 | Abbott Lab | AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS |
| RU2010118457A (ru) | 2007-10-12 | 2011-11-20 | Новартис АГ (CH) | Композиции, содержащие модуляторы рецептора сфингозин-1-фосфата (sip) |
| EP2358660A2 (en) | 2008-11-11 | 2011-08-24 | Novartis AG | Salts of fingolimod |
| AR074826A1 (es) | 2008-12-22 | 2011-02-16 | Novartis Ag | Regimen de dosificacion para un agonista de los receptores de s1p |
-
2012
- 2012-03-29 JO JOP/2012/0074A patent/JO3177B1/ar active
- 2012-03-29 AR ARP120101074A patent/AR085749A1/es not_active Application Discontinuation
- 2012-03-30 MY MYPI2017000050A patent/MY175633A/en unknown
- 2012-03-30 MA MA36277A patent/MA34981B1/fr unknown
- 2012-03-30 DK DK16176665.4T patent/DK3143990T3/da active
- 2012-03-30 AU AU2012236357A patent/AU2012236357B2/en active Active
- 2012-03-30 PT PT127141638T patent/PT2694037T/pt unknown
- 2012-03-30 BR BR112013024430-5A patent/BR112013024430B1/pt active IP Right Grant
- 2012-03-30 PE PE2013002121A patent/PE20140162A1/es active IP Right Grant
- 2012-03-30 SI SI201231732T patent/SI3143990T1/sl unknown
- 2012-03-30 EA EA201391442A patent/EA027721B1/ru not_active IP Right Cessation
- 2012-03-30 RS RS20200141A patent/RS59917B1/sr unknown
- 2012-03-30 EA EA201790436A patent/EA035686B1/ru not_active IP Right Cessation
- 2012-03-30 MY MYPI2013003216A patent/MY163746A/en unknown
- 2012-03-30 SG SG2013065867A patent/SG193256A1/en unknown
- 2012-03-30 SI SI201230821A patent/SI2694037T1/sl unknown
- 2012-03-30 CA CA2831600A patent/CA2831600C/en active Active
- 2012-03-30 DK DK12714163.8T patent/DK2694037T3/en active
- 2012-03-30 LT LTEP16176665.4T patent/LT3143990T/lt unknown
- 2012-03-30 PL PL12714163T patent/PL2694037T3/pl unknown
- 2012-03-30 JP JP2014502817A patent/JP6019101B2/ja active Active
- 2012-03-30 MX MX2013011415A patent/MX342522B/es active IP Right Grant
- 2012-03-30 WO PCT/US2012/031340 patent/WO2012135561A1/en active Application Filing
- 2012-03-30 ES ES16176665T patent/ES2773482T3/es active Active
- 2012-03-30 EP EP16176665.4A patent/EP3143990B1/en active Active
- 2012-03-30 HU HUE12714163A patent/HUE031286T2/hu unknown
- 2012-03-30 PE PE2017000900A patent/PE20170913A1/es not_active Application Discontinuation
- 2012-03-30 US US14/009,241 patent/US9592208B2/en active Active
- 2012-03-30 TW TW101111547A patent/TWI528958B/zh active
- 2012-03-30 PL PL16176665T patent/PL3143990T3/pl unknown
- 2012-03-30 EP EP12714163.8A patent/EP2694037B1/en active Active
- 2012-03-30 KR KR1020137025398A patent/KR102027014B1/ko active IP Right Grant
- 2012-03-30 PT PT161766654T patent/PT3143990T/pt unknown
- 2012-03-30 ES ES12714163.8T patent/ES2610966T3/es active Active
- 2012-03-30 CN CN201280017346.1A patent/CN103476400B/zh active Active
- 2012-03-30 LT LTEP12714163.8T patent/LT2694037T/lt unknown
-
2013
- 2013-09-02 IL IL228250A patent/IL228250B/en active IP Right Grant
- 2013-09-04 ZA ZA2013/06636A patent/ZA201306636B/en unknown
- 2013-09-27 CO CO13230722A patent/CO6771459A2/es unknown
- 2013-09-27 GT GT201300227A patent/GT201300227A/es unknown
- 2013-09-30 CL CL2013002810A patent/CL2013002810A1/es unknown
- 2013-10-01 EC ECSP13012912 patent/ECSP13012912A/es unknown
-
2014
- 2014-04-09 HK HK14103389.7A patent/HK1190309A1/zh unknown
-
2017
- 2017-01-09 HR HRP20170021TT patent/HRP20170021T1/hr unknown
- 2017-01-12 CY CY20171100045T patent/CY1118423T1/el unknown
- 2017-01-30 US US15/418,831 patent/US20170135967A1/en not_active Abandoned
-
2018
- 2018-03-09 US US15/916,371 patent/US20180193291A1/en not_active Abandoned
-
2019
- 2019-04-23 US US16/391,506 patent/US20190247335A1/en not_active Abandoned
-
2020
- 2020-02-14 HR HRP20200249TT patent/HRP20200249T1/hr unknown
- 2020-02-24 CY CY20201100169T patent/CY1122868T1/el unknown
- 2020-05-18 US US16/876,336 patent/US20200276137A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170021T1 (hr) | Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol | |
| JP2013525501A5 (hr) | ||
| AU2011207103B2 (en) | Anaesthetic formulation | |
| Mosher et al. | Complexation and cyclodextrins | |
| KR102013718B1 (ko) | Nsaid 및 사이클로덱스트린을 포함하는 신규한 약제학적 제제 | |
| CN104334164A (zh) | 基于木糖醇的抗黏膜组合物以及相关方法和组合物 | |
| JP5823093B2 (ja) | 低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 | |
| WO2008005819A2 (en) | Ophthalmic formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | |
| EA201370175A1 (ru) | Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство | |
| JP2009531450A5 (hr) | ||
| UA107186C2 (xx) | Тверді форми дозування бендамустину | |
| RU2015102575A (ru) | Жидкие композиции рацекадотрила | |
| JP2014521641A5 (hr) | ||
| US10463677B2 (en) | Composition containing sulfoalkyl ether cyclodextrin and latanoprost | |
| JP2019131596A5 (hr) | ||
| JP3597239B2 (ja) | 安定な点眼剤 | |
| EP3506947A1 (en) | Pharmaceutical formulations of regadenoson | |
| JP2018526420A5 (hr) | ||
| JP6239282B2 (ja) | 腎不全改善剤 | |
| JP2011502169A5 (hr) | ||
| AU2013200895B2 (en) | Anaesthetic formulation | |
| JP2006117704A5 (hr) | ||
| CN101574524A (zh) | 亲脂性药物磺烷基醚环糊精包合物及其制备方法 | |
| NZ706101A (en) | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |